ArticleNature communications2025
Endothelial RAB5IF is required for pathological and developmental retinal angiogenesis.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Retinal angiogenesis drives both normal vascular development and sight-threatening retinal vascular diseases. While mitochondria are known to fuel this process, the roles of many specific mitochondrial proteins are poorly understood. Here we show that the mitochondrial protein RAB5 interacting factor (RAB5IF) as a critical pro-angiogenic regulator of physiological retinal vascular development in neonatal mice (sex-balanced) and pathological retinal angiogenesis in two models: oxygen-induced retinopathy mice (sex-balanced) and laser-induced choroidal neovascularization mice (sex-balanced). Proteomic sequencing identified SUMO2 as a critical downstream protein of RAB5IF. RAB5IF silencing impeded mitochondrial respiration and ribosome biogenesis, specifically suppressing SUMO2 mRNA translation initiation and consequently lowering SUMO2 protein levels in retinal microvascular endothelial cells. We also identify that SUMO2-mediated SUMOylation of Gαi1/3 is required for their roles in mediating VEGF signaling. Mutations at the SUMOylation sites of Gαi1/3 hindered VEGF-induced signaling and pro-angiogenic activity. Together, these findings delineate a RAB5IF-SUMO2-Gαi1/3 signaling axis essential for retinal angiogenesis, presenting new therapeutic targets for neovascular eye diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.